TROPOSplice propone una estrategia inspirada en la evolución para mejorar la relajación del corazón en pacientes con miocardiopatía hipertrófica e insuficiencia cardiaca con fracción de eyección preservada
TROPOSplice proposes an evolution-inspired strategy to improve cardiac relaxation in patients with hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
A new analysis of the DapaTAVI trial, published in the European Journal of Heart Failure, confirms that dapagliflozin improves outcomes after TAVI regardless of cardiac function.
The research, presented in a Hot Line session at the European Society of Cardiology Congress in Munich and published simultaneously in The New England Journal of Medicine, proposes a paradigm shift towards prevention based on early detection through vascular imaging
